Strategic Partners Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Strategic Partners heeft een totaal eigen vermogen van DKK16.1M en een totale schuld van DKK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk DKK17.9M en DKK1.8M. De EBIT Strategic Partners is DKK1.8M waardoor de rentedekking -2.1 is. Het heeft contanten en kortetermijnbeleggingen van DKK17.8M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

DKK 0

Schuld

Rente dekkingsratio	-2.1x
Contant	DKK 17.75m
Aandelen	DKK 16.09m
Totaal verplichtingen	DKK 1.76m
Totaal activa	DKK 17.85m

Recente financiële gezondheidsupdates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( DKK17.9M ) 1TB0 } overtreffen de korte termijn passiva ( DKK1.8M ).

Langlopende schulden: 1TB0 heeft geen langlopende schulden.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 1TB0 is schuldenvrij.

Schuld verminderen: 1TB0 had 5 jaar geleden geen schulden.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: 1TB0 heeft op basis van de huidige vrije kasstroom voldoende kasstroom voor meer dan een jaar.

Voorspelling contante baan: 1TB0 heeft voldoende kasruimte voor 1.5 jaar als de vrije kasstroom blijft groeien met een historisch percentage van 10.6 % per jaar.

Strategic Partners Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Recent updates

New major risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Financial data availability

No independent directors

Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI).

Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO

Orphazyme A/S Announces Board Changes

Orphazyme A/S to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Orphazyme A/S Revises Earnings Guidance for the Year 2022

Orphazyme American Depositary Shares - Sponsored to Be Deleted from Other OTC

Orphazyme A/S Announces Board Appointment

Orphazyme A/S Provides Earnings Guidance for the Full Year of 2022

KemPharm Denmark A/S acquired Substantially All Assets and Business Activities of Orphazyme A/S for $18 million.

Orphazyme A/S Announces Executive Changes

Orphazyme A/S(CPSE:ORPHA) dropped from S&P Global BMI Index

Orphazyme A/S announced delayed amended 20-F filing

Orphazyme A/S announced delayed 20-F filing

Orphazyme A/S to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Orphazyme A/S, Annual General Meeting, May 21, 2022

Forecast to breakeven in 2024

Orphazyme A/S Announces Update on Regulatory Review of Arimoclomol in the European Union

Orphazyme A/S Elects Andrew Mercieca as Member of the Board of Directors

Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States

Orphazyme to Present Additional Data on Arimoclomol’s Mechanism of Action During 2022 Annual Worldsymposium™

Orphazyme A/S Announces CEO Changes

Orphazyme A/S Revises Earnings Guidance for the Year 2021

Forecast to breakeven in 2024

Orphazyme A/S Maintains its Outlook for the Full Year 2021

Orphazyme A/S Announces Publication of Results from Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C in the Journal of Inherited Metabolic Disease

Independent Director Martijn Kleijwegt has left the company

Independent Director Remi P. Droller has left the company

Independent Director Anders Hedegaard has left the company

CytRx Corporation Announces 24-Month Interim Results of an Open-Label Extension Trial of Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Orphazyme Provides Earnings Guidance for the Year of 2021

Orphazyme A/S Announces Topline Data from Pivotal Trial of Arimoclomol in Amyotrophic Lateral Sclerosis

Independent Director has left the company

Orphazyme A/S Appoints Christophe Bourdon as Chief Executive Officer, Effective on April 1, 2021

Orphazyme A/S to Showcase Data on Arimoclomol in Niemann-Pick Disease Type C During the 2021 Annual Worldsymposium™

New 90-day high: €10.56

CytRx Corporation Issues Statement Regarding U.S. Regulatory Review of Arimoclomol for Niemann-Pick Disease Type C

Orphazyme A/S Announces the U.S. Food and Drug Administration Has Extended the Review Period of the New Drug Application

New 90-day low: €7.41

Orphazyme A/S Announces Executive Changes

Orphazyme A/S, Annual General Meeting, Mar 25, 2021

Orphazyme A/S to Report First Half, 2021 Results on Aug 24, 2021

Orphazyme A/S Submits European Marketing Authorisation Application for Arimoclomol for Treatment of Niemann-Pick Disease Type C

CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

New 90-day low: €8.67

Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.

Orphazyme A/S Provides Update on Previously Announced Global Offering

New 90-day low: €9.92

Orphazyme A/S Elects Carrolee Barlow as Board of Director

New 90-day low - €11.52

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven